Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.36 |
| ▸ | GJB2 | P29033 | 1/20 | 0.35 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16126848 | 0.90 | GBA1 (0.42) | GBA1GBA2SPHK2SPHK1UGCG | |
| SCHEMBL14554178 | 0.83 | GBA1 (0.41) | GBA1SMN1; SMN2SPHK2SPHK1GJB2 | |
| SCHEMBL24163079 | 0.82 | GAA (0.32) | — | |
| SCHEMBL17861063 | 0.81 | GBA1 (0.47) | GBA1GBA2SPHK2SPHK1 | |
| SCHEMBL12942274 | 0.80 | SMN1; SMN2 (0.49) | GBA1SMN1; SMN2GBA2SPHK2SPHK1 | |
| SCHEMBL18529141 | 0.78 | ALDH1A1 (0.47) | GBA1GBA2UGCG | |
| SCHEMBL18529131 | 0.78 | ALDH1A1 (0.47) | GBA1GBA2UGCG | |
| SCHEMBL18529199 | 0.78 | ALDH1A1 (0.47) | GBA1GBA2UGCG | |
| SCHEMBL15886973 | 0.78 | GBA1 (0.46) | GBA1SMN1; SMN2GBA2SPHK2SPHK1 | |
| SCHEMBL8131402 | 0.78 | GBA1 (0.42) | GBA1SMN1; SMN2SPHK2SPHK1GJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | TLR5, THPO, IDO1 | GBA1 1473/4885SMN1; SMN2 1824/4885GBA2 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.